In contrast, LILRB2 blockade repolarized TAMs to M1-like phenotypes by suppressing SHP1/2 phosphorylation and activating the NF-κB pathway, thereby augmenting anti-tumor immunity 155, 156. This evidence concerns the gene LILRB2 and neoplasm.